<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The treatment of 77 children suffering from acquired <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AAA) in the Petersburg Pediatric Hematological Center allowed the authors to distinguish three groups of patients according to the disease severity: severe, moderate and mild </plain></SENT>
<SENT sid="1" pm="."><plain>The groups differed by clinicohematological parameters and treatment results </plain></SENT>
<SENT sid="2" pm="."><plain>With reference to the above classification conventional combined treatment with hormones and splenectomy is uneffective in groups 1 and 2, but is able to induce remission in half the patients with mild disease </plain></SENT>
<SENT sid="3" pm="."><plain>Immunosuppression with antilymphocytic globulin and large-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> markedly contributed to survival prolongation in severe and moderate AAA (69 and 90% of cases with long-term remissions, respectively), being a failure in group 1 patients who are primarily scheduled for bone marrow transplantation </plain></SENT>
</text></document>